BRCA in breast cancer: ESMO Clinical Practice Guidelines.

BRCA in breast cancer: ESMO Clinical Practice Guidelines J. Balmana, O. Diez, I. Rubio & M. Castiglione On behalf of the ESMO Guidelines Working Group* Department of Medical Oncology; Oncogenetics Laboratory, University Hospital Vall d’Hebron; Vall d’Hebron Institute of Oncology (VHIO); Breast Cancer Surgical Unit, Breast Cancer Center, University Hospital Vall d’Hebron, Barcelona, Spain; RGT, University of Geneva, Geneva, Switzerland

[1]  J. Kwon,et al.  Expanding the criteria for BRCA mutation testing in breast cancer survivors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[3]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[4]  K. Griffith,et al.  Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy , 2010, Breast Cancer Research and Treatment.

[5]  J. Lubiński,et al.  Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Klijn,et al.  Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Kundt,et al.  The Oncological Safety of Skin Sparing Mastectomy with Conservation of the Nipple-Areola Complex and Autologous Reconstruction: An Extended Follow-Up Study , 2009, Annals of surgery.

[8]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[9]  R. Wilkins.  Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[10]  Nazneen Rahman,et al.  Genetic predisposition to breast cancer: past, present, and future. , 2008, Annual review of genomics and human genetics.

[11]  Y. Drew,et al.  The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers , 2008, Annals of the New York Academy of Sciences.

[12]  T. Rebbeck,et al.  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Olufunmilayo I. Olopade,et al.  Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations , 2007, Nature Reviews Cancer.

[14]  Francesco Sardanelli,et al.  Management of an inherited predisposition to breast cancer. , 2007, The New England journal of medicine.

[15]  S. Singletary,et al.  Selective use of sentinel lymph node surgery during prophylactic mastectomy , 2006, Cancer.

[16]  B. Weber,et al.  Clinical management of BRCA1 and BRCA2 mutation carriers , 2006, Oncogene.

[17]  O. Olopade,et al.  Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  O. Olopade,et al.  Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update , 2006, International journal of cancer.

[19]  J. Chang-Claude,et al.  Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). , 2006, Journal of the National Cancer Institute.

[20]  T. Walsh,et al.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.

[21]  O. Olopade,et al.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. , 2006, The Lancet. Oncology.

[22]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[23]  Susan L Neuhausen,et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[25]  G. Robb,et al.  Oncologic Safety of Skin-Sparing Mastectomy , 2003, Annals of Surgical Oncology.

[26]  T. Sellers,et al.  Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. , 2001, Journal of the National Cancer Institute.

[27]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[28]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[29]  J. Dungan.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[30]  A. Degnim.  Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality , 2011 .

[31]  B. Weber,et al.  Clinical management of BRCA1 and BRCA2 mutation carriers , 2006, Nature Clinical Practice Oncology.

[32]  L. J. Schelven,et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group , 2004 .

[33]  Anne,et al.  BREAST CANCER AFTER PROPHYLACTIC BILATERAL MASTECTOMY IN WOMEN WITH A BRCA 1 OR BRCA 2 MUTATION , 2001 .